HomeAI · summaries
Storia in 2 fonti
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other…
- ·
endpoints.news
Epicrispr secures $90M after early data on epigenetic FSHD treatment
Epicrispr has raised a Series C round after sharing promising early data for EPI-321, a potential new way to treat facioscapulohumeral muscular dystrophy.